U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Hydroxypropyl cellulose (HPC) is an ether of cellulose where some of the hydroxyl groups of the cellulose have been hydroxypropylated. Hydroxypropyl cellulose is used as an excipient, and topical ophthalmic protectant and lubricant. Hydroxypropyl cellulose, manufactured by Aton Pharma, is a formulation of HPC used for artificial tears. It is used to treat medical conditions characterized by insufficient tear production such as keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure, and neuroparalytic keratitis. HPC is also used as a lubricant for artificial eyes. Hydroxypropyl cellulose acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states. Hydroxypropyl cellulose usually reduces the signs and symptoms resulting from moderate to severe dry eye syndromes, such as conjunctival hyperemia, corneal and conjunctival staining with rose bengal, exudation, itching, burning, foreign body sensation, smarting, photophobia, dryness, and blurred and cloudy vision. Progression visual deterioration which occurs in some patients may be retarded, halted, or sometimes reversed.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LACRISERT

Approved Use

LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions

Launch Date

1981
Primary
LACRISERT

Approved Use

LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions

Launch Date

1981
Primary
LACRISERT

Approved Use

LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions

Launch Date

1981
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

One LACRISERT ophthalmic insert (5mg/insert) in each eye once daily
Route of Administration: Topical
Polymer solutions were prepared incrementally, increasing polymer (HPC) concentration by 0.5% per increment (w/v) between 1.0% and 5.0%. A stock solution containing 1 M MES and 0.5 M TRIS (pH 6.1) was prepared and utilized for all buffers throughout the experiments.
Substance Class Polymer
Created
by admin
on Sat Dec 16 03:08:21 GMT 2023
Edited
by admin
on Sat Dec 16 03:08:21 GMT 2023
Record UNII
RFW2ET671P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDROXYPROPYL CELLULOSE (1600000 WAMW)
Common Name English
HYDROXYPROPYL CELLULOSE (TYPE H)
Common Name English
KLUCEL HXF
Brand Name English
KLUCEL HF
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175535
Created by admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
Code System Code Type Description
DAILYMED
RFW2ET671P
Created by admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
PRIMARY
CAS
9004-64-2
Created by admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
GENERIC (FAMILY)
RXCUI
27291
Created by admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
ALTERNATIVE RxNorm
RXCUI
2048727
Created by admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
ALTERNATIVE
RXCUI
1811461
Created by admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
PRIMARY
FDA UNII
RFW2ET671P
Created by admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
PRIMARY
NCI_THESAURUS
C29139
Created by admin on Sat Dec 16 03:08:21 GMT 2023 , Edited by admin on Sat Dec 16 03:08:21 GMT 2023
PRIMARY
Display Structure of HYDROXYPROPYL CELLULOSE (1600000 WAMW)
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER AVERAGE CHEMICAL
MOL_WEIGHT:WEIGHT AVERAGE CHEMICAL
DEGREE OF SUBSTITUTION CHEMICAL
Unknown Structure
HYDROXYPROPYL FRAGMENT
(not present in database)
MOLAR SUBSTITUTION CHEMICAL
Unknown Structure
HYDROXYPROPYL FRAGMENT
(not present in database)